Ovarian Cancer: Best Practices for Managing PARP Inhibitor Side Effects

October 4, 2023 9:00 am

Oncologists treating ovarian cancer need to be proactive to prevent or reduce the likelihood of adverse effects associated with poly (ADP-ribose) polymerase (PARP) inhibitors, noted authors of a review in the ASCO Educational Book.

William Tew, MD, of Memorial Sloan … Read more

DESTINY-PanTumor-02: Trastuzumab Deruxtecan Has Activity Against a Range of HER2-Expressing Solid Tumors

June 7, 2023 6:55 am

Key Points:

  • Interim results of the phase 2 trial DESTINY-PanTumor-02 show that T-DXd has broad activity across tumor types and a toxicity profile consistent with previous studies.
  • T-DXd had the lowest activity in pancreatic cancer, and this cohort was stopped
Read more

Olaparib-durvalumab regimen prolongs PFS for certain women with advanced ovarian cancer

June 3, 2023 7:02 am

Key takeaways:

  • Researchers reported statistically significant improvement in median PFS with the combination added to standard of care in non-BRCA-mutated disease.
  • The relative contribution of durvalumab requires further study.

 

CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab … Read more

Quintuple Regimen Prolongs PFS in Advanced, High-Grade Epithelial Ovarian Cancer +/- BRCA Mutations

April 5, 2023 4:55 pm

by Nichole Tucker

The DUO-O press release went out on 4/5/2023. It suggests that adding immunotherapy to PARP inhibitor maintenance therapy for newly diagnosed ovarian cancer patients that have finished first-line platinum treatment may be beneficial. We are eagerly awaiting Read more

Neoadjuvant olaparib feasible for women with germline-mutant ovarian cancer

March 27, 2023 9:13 am

by Devin McLaughlin

Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Researchers observed favorable surgical outcomes — even … Read more

Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer

March 27, 2023 9:11 am

by Jason Harris

Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with resistant/refractory ovarian cancer, according to findings from the phase 1 C-800 study (NCT03860272) presented at the 2023 SGO Annual Meeting on Women’s Cancer.1Read more

Anti-cancer drugs, olaparib and adavosertib, work best when given sequentially in patients with advanced tumours driven by DNA damage response mutations: results from Phase Ib STAR clinical trial

October 27, 2022 2:26 pm

Barcelona, Spain: Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olparib and adavosertib, if they are given in sequence rather than concurrently.

Presenting results from the … Read more

ASCO Addresses PARP Controversy in Guideline Update

September 28, 2022 12:01 pm

— A response to “practice-changing data” in the first- and second-line setting

by Mike Bassett

An updated recommendation from the American Society of Clinical Oncology (ASCO) warns against the routine use of PARP inhibitor monotherapy in the second- or later-line

Read more

Maintenance Therapy the ‘Biggest Breakthrough in Decades’ for Ovarian Cancer

September 15, 2022 1:54 pm

by Karen Blum

Although maintenance treatments have helped patients with ovarian cancer live longer, experts note there are still some unmet needs that must be addressed.

Karen Hanna was first diagnosed with ovarian cancer in April 2013. At the time,

Read more

Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials

September 9, 2022 10:37 am

by Mike Bassett

— Results from SOLO-1 and PAOLA-1 show “clinically meaningful” long-term results with olaparib

PARIS — Olaparib (Lynparza) maintenance therapy appears to offer a long-term overall survival (OS) benefit for women with ovarian cancer, according to two phase … Read more

Real-World Data Identify Significant Differences in Tolerability Among Approved PARP Inhibitors in Ovarian Cancer

June 14, 2022 11:57 am

by Lindsey Fischer

A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.

Patients with ovarian cancer treated with FDA-approved

Read more

Olaparib Dose Reductions/Interruptions Do Not Affect Survival in Platinum-Sensitive Ovarian Cancer

March 11, 2022 10:00 am

by Ariana Pelosci

Adverse effects associated with treatment with olaparib that led to dose reductions and interruptions did not impact survival benefit for patients with platinum-sensitive ovarian cancer.

Patients with platinum-sensitive recurrent ovarian cancer who experienced adverse effects (AEs) during

Read more

Ceralasertib Olaparib Combo Elicits Promising Activity In Parp Resistant Ovarian Cancer

July 15, 2021 2:43 pm

The combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.

The combination of ceralasertib and olaparib (Lynparza) induced clinical activity and was well tolerated in … Read more

PARP Inhibition Shows Efficacy in Ovarian Cancer Regardless of Number of Prior Lines of Chemotherapy, BRCA Mutation Status

March 22, 2021 3:00 pm

By Chase Doyle

Treatment with olaparib is safe and effective for patients with platinum-sensitive relapsed ovarian cancer, regardless of the number of prior lines of chemotherapy received and BRCA mutation status, according to data presented from the phase II LIGHT … Read more

ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer

October 28, 2020 4:00 pm

By Andrew D. Bowser

New guidelines recommend against retreatment with poly (ADP-ribose) polymerase (PARP) inhibitors in women with epithelial ovarian, tubal, or primary peritoneal cancer (EOC). However, trials investigating retreatment are underway, so this recommendation may change.

The guidelines, from … Read more

KSQ Boosts PARP Inhibition In Models Of Cancer With USP1 Inhibitor

October 27, 2020 7:00 pm

KSQ Therapeutics is hoping to provide hope for ovarian and breast cancer patients that have developed a resistance to drugs and those who don’t respond at all by developing a drug that may be able to boost the effectiveness of … Read more

Triple therapy Shows Promise in Non-Germline BRCA-Mutated Ovarian Cancer

October 10, 2020 5:00 pm

By Savannah Demko

Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

“Preclinical studies suggest the potential for synergy between … Read more

Halting Cancer by Halting DNA Repair

September 25, 2020 11:00 am

By Liam Drew

PARP inhibitors are rapidly transforming the treatment of ovarian, breast, prostate and other types of cancer. To develop these drugs, researchers supported by Cancer Research UK had to decipher how blocking DNA repair could expose a weak … Read more

Olaparib Improves Median Time Without Disease Progression in BRCAm Ovarian Cancer

September 18, 2020 3:00 pm

Olaparib (Lynparza®; AstraZeneca/Merck & Co.*) has demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response … Read more

ASCO Releases New Guidelines on PARP Inhibitor Use for Management of Ovarian Cancer

September 1, 2020 2:00 pm

By Hannah Slater

The recommendations were based on a review of 17 clinical trials, FDA approvals, and consensus where evidence was lacking.

The American Society for Clinical Oncology (ASCO) published new guidelines on the use of PARP inhibitors in the … Read more